Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
May 4, 2011
SAN DIEGO, May 4, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced it will report first quarter 2011 financial results after the NASDAQ Global Select Market closes on Tuesday, May 10, 2011. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, will host a conference call and webcast at 5:00 p....
Mar 29, 2011
SAN DIEGO, March 29, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has agreed to sell 12,150,000 shares of its common stock, at a price of $1.46 per share, and 12,150 shares of its Series C Convertible Preferred Stock, at a price of $1,460 per share, in a registered direct public offering to entities affili...
Mar 11, 2011
SAN DIEGO, March 11, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the fourth quarter and full year ended December 31, 2010, and reviewed recent developments. "Our focus is working with Eisai to obtain FDA approval of lorcaserin, preparing to submit an application for European approval of lo...
Mar 10, 2011
SAN DIEGO, March 10, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it was issued United States Reissue Patent No. RE42,190 with claims to methods of identifying compounds that modulate the activity of the GPR119 receptor. This invention stems from the discovery by Arena's scientists of the GPR119 receptor, a t...
Mar 8, 2011
SAN DIEGO, March 8, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report fourth quarter and full year 2010 financial results before the NASDAQ Global Select Market opens on Friday, March 11, 2011. That same morning, Jack Lief, Arena's President and Chief Executive Officer, will host a conference call at 8:3...
Feb 10, 2011
SAN DIEGO, Feb. 10, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the resignation of Robert E. Hoffman, Vice President, Finance and Chief Financial Officer. Mr. Hoffman, who has accepted a new position in the healthcare industry, will remain in his current role at Arena until the reporting of the company's year-end...
Feb 9, 2011
SAN DIEGO, Feb. 9, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 13th Annual BIO CEO & Investor Conference on Monday, February 14, 2011, at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. Jack Lief, Arena's President and ...
Jan 27, 2011
SAN DIEGO, Jan. 27, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today a reduction of its US workforce of approximately 25%, or 66 employees. As a result of the workforce reduction, which Arena plans to complete around March 28, 2011, the company expects to incur restructuring charges, primarily in the first quarter of ...
Jan 6, 2011
SAN DIEGO, Jan. 6, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2011, at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time) at the Westin St. Francis Hotel in San Francisco, California. Jack Lief, A...
Dec 22, 2010
SAN DIEGO and WOODCLIFF LAKE, N.J., Dec. 22, 2010 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today the completion of an end-of-review meeting with the US Food and Drug Administration (FDA) for the lorcaserin New Drug Application (NDA). "The meeting discussions reinforce our position that we have a path f...
Dec 21, 2010
SAN DIEGO, Dec. 21, 2010 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Jack Lief, Arena's President and Chief Executive Officer, will host a conference call and webcast tomorrow, Wednesday, December 22, 2010, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to provide an update following the completion of an end-...
Dec 10, 2010
SAN DIEGO, Dec. 10, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial hypertension, or PAH. "An orally bioavailable ...
Nov 24, 2010
SAN DIEGO, Nov. 24, 2010 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Piper Jaffray 22nd Annual Health Care Conference on December 1, 2010, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) at the New York Palace Hotel in New York City. Jack Lief, Arena's President and C...
Nov 9, 2010
SAN DIEGO, Nov. 9, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the third quarter ended September 30, 2010. Arena also reported earlier today top-line results from its lorcaserin Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabete...
Nov 9, 2010
SAN DIEGO and WOODCLIFF LAKE, N.J., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. reported today that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes. In this trial, lorcaserin met a...
= add release to Briefcase